Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Capital Expenditures (2016 - 2023)

Avalo Therapeutics (AVTX) has disclosed Capital Expenditures for 8 consecutive years, with $158000.0 as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Capital Expenditures changed N/A year-over-year to $158000.0, compared with a TTM value of $158000.0 through Dec 2023, changed N/A, and an annual FY2023 reading of $158000.0, changed N/A over the prior year.
  • Capital Expenditures was $158000.0 for Q1 2023 at Avalo Therapeutics, up from -$95000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $165969.0 in Q1 2019 and bottomed at -$95000.0 in Q4 2022.
  • Average Capital Expenditures over 5 years is $54183.0, with a median of $63000.0 recorded in 2020.
  • The sharpest move saw Capital Expenditures surged 1256.15% in 2019, then crashed 963.64% in 2022.
  • Year by year, Capital Expenditures stood at $2.0 in 2019, then surged by 3149900.0% to $63000.0 in 2020, then tumbled by 82.54% to $11000.0 in 2021, then plummeted by 963.64% to -$95000.0 in 2022, then soared by 266.32% to $158000.0 in 2023.
  • Business Quant data shows Capital Expenditures for AVTX at $158000.0 in Q1 2023, -$95000.0 in Q4 2022, and $95000.0 in Q3 2022.